Abstract:Background: This study aimed to explore the relationship between MALAT1 and the prognosis of patients with hepatocellular carcinoma (HCC). Methods: We constructed a MALAT1 protein-protein interaction network using the STRING database and a network of competing endogenous RNAs (ceRNAs) using the StarBase database. Using data from the GEPIA2 database, we studied the association between genes in these networks and survival of patients with HCC. The potential mechanisms underlying the relationship between MALAT1 and HCC prognosis were studied using combined data from RNA sequencing, DNA methylation, and somatic mutation data from The Cancer Genome Atlas (TCGA) liver cancer cohort. Tumor tissues and 19 paired adjacent non-tumor tissues (PANTs) from HCC patients who underwent radical resection were analyzed for MALAT1 mRNA levels using real-time PCR, and associations of MALAT1 expression with clinicopathological features or prognosis of patients were analyzed using log-rank test and Gehan-Breslow-Wilcoxon test. Results: Five interacting proteins and five target genes of MALAT1 in the ceRNA network significantly correlated with poor survival of patients with HCC ( p < 0.05). High MALAT1 expression was associated with mutations in two genes leading to poor prognosis and may upregulate some prognostic risk genes through methylation. MALAT1 was significantly co-expressed with various signatures of genes involved in HCC progression, including the cell cycle, DNA damage repair, mismatch repair, homologous recombination, molecular cancer m6A, exosome, ferroptosis, infiltration of lymphocyte ( p < 0.05). The expression of MALAT1 was markedly upregulated in HCC tissues compared with PANTs. In Kaplan-Meier analysis, patients with high MALAT1 expression had significantly shorter progression-free survival (PFS) ( p = 0.033) and overall survival (OS) ( p = 0.023) than those with low MALAT1 expression. Median PFS was 19.2 months for patients with high MALAT1 expression and 52.8 months for patients with low expression, while the corresponding median OS was 40.5 and 78.3 months. In subgroup analysis of patients with vascular invasion, cirrhosis, and HBsAg positive or AFP positive, MALAT1 overexpression was significantly associated with shorter PFS and OS. Models for predicting PFS and OS constructed based on MALAT1 expression and clinicopathological features had moderate predictive power, with areas under the receiver operating characteristic curves of 0.661–0.731. Additionally, MALAT1 expression level was significantly associated with liver cirrhosis, vascular invasion, and tumor capsular infiltration ( p < 0.05 for all). Conclusion: MALAT1 is overexpressed in HCC, and higher expression is associated with worse prognosis. MALAT1 mRNA level may serve as a prognostic marker for patients with HCC after hepatectomy.

The Predicting Effect of Long Chain Non-coding RNA MALAT1 on Tumor Recurrence and Patient's Prognosis for Non-small Cell Lung Cancer

Long Noncoding Rna Malat1 As A Putative Biomarker Of Lymph Node Metastasis: A Meta-Analysis

High Expression of Lncrna MALAT1 Suggests a Biomarker of Poor Prognosis in Colorectal Cancer.

Prognostic Value of Long Non-Coding RNA MALAT1 in Cancer Patients

Long Noncoding RNA MALAT-1 Can Predict Metastasis and a Poor Prognosis: a Meta-Analysis

High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival

Long Noncoding Rna Malat-1 Can Predict Poor Prognosis: A Meta-Analysis

Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: A study based on multi-omics analysis and RT-PCR validation

Long Non-Coding RNA MALAT-1 Overexpression Predicts Tumor Recurrence of Hepatocellular Carcinoma after Liver Transplantation

Elevated Long Noncoding RNA MALAT-1 Expression is Predictive of Poor Prognosis in Patients with Breast Cancer: a Meta-Analysis

Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development

Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia

Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma

Clinical Value of Lncrna MALAT1 As a Prognostic Marker in Human Cancer: Systematic Review and Meta-Analysis.

Long Noncoding RNA MALAT1 and Colorectal Cancer: A Propensity Score Analysis of Two Prospective Cohorts

Long Non-Coding RNA Metastasis Associated in Lung Adenocarcinoma Transcript 1 (MALAT1) Interacts with Estrogen Receptor and Predicted Poor Survival in Breast Cancer.

Long Non-Coding MELTF Antisense RNA 1 Promotes and Prognosis the Progression of Non-Small Cell Lung Cancer by Targeting Mir-1299

Novel Insights Into MALAT1 Function as a MicroRNA Sponge in NSCLC

LncRNA MALAT1 accelerates non‐small cell lung cancer progression via regulating miR‐185‐5p/MDM4 axis

The Association between Abnormal Long Noncoding RNA MALAT-1 Expression and Cancer Lymph Node Metastasis: A Meta-Analysis

A meta-analysis of the clinicopathological significance of the lncRNA MALAT1 in human gastric cancer